BiotechTube

PLX3397 + Pembrolizumab

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer

Trial Timeline

Jul 2, 2015 → Oct 12, 2018

NCT ID
NCT02452424

About PLX3397 + Pembrolizumab

PLX3397 + Pembrolizumab is a phase 1/2 stage product being developed by Daiichi Sankyo for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02452424. Target conditions include Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02452424Phase 1/2Terminated

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
mRNA-4157 + PembrolizumabMerckPhase 2
39
AVT32-DRL_PB + KeytrudaDr. Reddy's LaboratoriesPhase 1
33
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35
Pembrolizumab + LenvatinibEisaiPhase 2
39